Carsgen

Developer of CAR-T cell therapies for the treatment of hematological malignancies and solid tumors

placeShanghai, Shanghai, China calendar_todayFounded 2014 groups525 employees language carsgen.com

Social engagement

Social engagement: 13.4K social following, 10 posts in the last 12 months — below the industry typical range.

Investor mix

11 investors on record; lead investors include DAOL Investment, Photon Fund, BioVeda China Fund, Loayal Valley Capital.

Investor typeCountShare
Venture capital545%
Private equity436%
Accelerator & incubator19%
Other / undisclosed19%

Recent activity

22 Jun 2026
Milestone
regulatory
15 Jun 2026
Event
EHA 2026 EHA 2026
12 Jan 2026
Partnership
Dispatch Bio
Coming soon